Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-α

Journal of Pharmacology and Experimental Therapeutics

Volumn 303, Issue 3, 2002, Pages 1334-1343

  Sewell, K Lea ^a   Geary, Richard S ^a   Baker, Brenda F ^a   Glover, Josephine M ^a   Mant, Timothy G K ^b   Yu, Rosie Z ^a   Tami, Joseph A ^a   Dorr, F Andrew ^a  

^a ISIS PHARMACEUTICALS   (United States)

^b Guy's Drug Research Unit Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ISIS 104838; PHORBOL 13 ACETATE 12 MYRISTATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BIOAVAILABILITY; CELL STIMULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA CELL; CYTOKINE PRODUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG IDENTIFICATION; HUMAN; IN VIVO STUDY; MALE; MONOCYTE; NEWBORN; NORMAL HUMAN; OBESITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN TARGETING;

ADOLESCENT; ADULT; AREA UNDER CURVE; DRUG DELIVERY SYSTEMS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; OLIGONUCLEOTIDES, ANTISENSE; REGRESSION ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036896204     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.036749     Document Type: Article

References (41)

1. Baker BF and Monia BP (1999) Novel mechanism for antisense-mediated regulation of gene expression. Biochim Biophys Acta 1489:3-18.
2. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, et al. (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343:1586-1593.
3. Bennett CF, Butler M, Cook PD, Geary RS, Levin AA, Mehta R, Teng CL, Deshmukh H, Tillman L, and Hardee G (2000) Antisense oligonucleotide-based therapeutics, in Gene Therapy (Templeton NS and Lasic DD, eds) pp 305-332, Marcel Dekker, Inc., New York.
4. Beutler BA (1999) The role of TNF in health and disease. J Rheumatol 57:16-21.
5. Boggs RT, McGraw K, Condon T, Flournoy S, Villiet P, Bennett CF, and Monia B (1997) Characterization and modulation of immune stimulation by modified oligonucleotides. Antisense Nuc Acid Drug Dev 7:461-467.
6. Choy EHS and Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907-916.
7. Crooke ST (1999) Molecular mechanisms of antisense drugs: Human RNase H. Antisense Nucleic Acid Drug Dev 9:377-379.
8. Cummins L, Geary RS, Watanabe T, Chappell A, Matson J, and Levin AA (2001) Metabolism characteristics of a modified antisense oligonucleotide, ISIS 104838. AAPS PharmaSci 3 (Suppl):T3711.
9. Dean NM, Butler M, Monia BP, and Manoharan M (2001) Pharmacology of 2′-O-(2-methoxy)ethyl-modifed antisense oligonucleotides, in Antisense Drug Technology: Principles, Strategies and Applications (Crooke ST ed) pp 319-338, Marcel Dekker, Inc., New York.
10. Geary RS, Mathison B, Watanabe T, Savides MC, Henry SP, and Levin AA (2001a) Second generation antisense oligonucleotide pharmacokinetics and mass balance following intravenous administration in rats. The Toxicologist 60:343.
11. Geary RS, Watanabe TA, Truong L, Freier S, Lesnik E, Sioufi NB, Sasmor H, Manoharan M, and Levin AA (2001b) Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther 296:890-897.
12. Gibson UEM, Heid CA, and Williams PM (1996) A novel method for real time quantitative RT-PCR. Genome Res 6:995-1001.
13. Glover JM, Leeds JM, Mant TGK, Amin D, Kisner DL, Zuckerman JE, Geary RS, Levin AA, and Shanahan WR (1997) Phase 1 safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligonucleotide (ISIS 2302). J Pharmacol Exp Ther 282:1173-1180.
14. Henry SP, Giclas PC, Leeds J, Pangburn M, Auletta C, Levin AA, and Kombrust DJ (1997) Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action. J Pharmacol Exp Therap 281:810-816.
15. Henry S, Stecker K, Brooks D, Monteith D, Conklin B, and Bennett CF (2000) Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J Pharmacol Exp Ther 292:468-479.
16. Henry SP, Geary RS, Yu R, and Levin AA (2001) Drug properties of second-generation antisense oligonucleotides: How do they measure up to their predecessors? Curr Opin Invest Drugs 2:1444-1449.
17. Henry SP, Jagels MA, Hugli TE, Manalil S, Geary RS, Giclas PC and Levin AA (2002) Mechanism of alternative complement pathway disregulation by a phosphorothioate oligodeoxynucleotide in monkey and human serum. Mol Immunol, in press.
18. Leeds JM, Graham MJ, Truong L, and Cummins LL (1996) Quantitation of phosphorothioate oligonucleotides in human plasma. Anal Biochem 235:36-43.
19. Leeds JM, Henry SP, Geary R, Burckin T, and Levin AA (2000) Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys. Antisense Nucleic Acid Drug Dev 10:435-441.
20. Levin AA, Henry SP, Monteith D, and Templin MV (2001) Toxicity of antisense oligonucleotides, in Antisense Drug Technology (Crooke ST, ed) pp 201-267, Marcel Dekker, Inc., New York.
21. Lipsky PE, van der Heijde DM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343:1594-1602.
22. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, MacFarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, et al. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-TNF-alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552-1563.
23. Maini RN, St. Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M and Lipsky P (1999) Infliximab (chimeric anti-TNF-alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. Lancet 354:1932-1939.
24. Maksymowych WP, Blackburn WD, Tami JA, and Shanahan WR (2002) A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to ICAM-1 in the treatment of severe rheumatoid arthritis. J Rheumatol 29:447-453.
25. McKay RA, Miraglia LJ, Cummins LL, Owens SR, Sasmor H, and Dean NM (1999) Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression. J Biol Chem 274:1715-1722.
26. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, et al. (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130:478-486.
27. Perrier MGD (1982) Noncompartmental analysis based on statistical moment theory, in Pharmacokinetics (Gibaldi M and Perrier D, eds) Vol 15, pp 409-417, Marcel Dekker, Inc., New York.
28. Phillips JA, Craig SJ, Bayley D, Christian RA, Geary R, and Nicklin PL (1997) Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem Pharmacol 54:657-668.
29. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand MD, Podolsky DK, Sands BE, Braakman T, DeWoody KL, et al. (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340:1398-1405.
30. Schattenkirchner M, Wastlhuber J, Rau R, Herborn G, Kroot EJ, van Riel P, van de Putte BA, Allaart CF, Breedveld FC, Fenner H, et al. (2000) Long-term use of the fully human anti-TNF antibody D2E7 in combination with methotrexate in active rheumatoid arthritis. Arthritis Rheum 43 (Suppl 9):S228.
31. Sheehan JP and Lan HC (1998) Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood 92:1617-1625.
32. Sheehan JP and Phan TM (2001) Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex by an allosteric mechanism. Biochemistry 40:4980-4989.
33. Stein CA (2001) The experimental use of antisense oligonucleotides: A guide for the perplexed. J Clin Investig 108:641-644.
34. Tak PP and Bresnihan B (2000) The pathogenesis and prevention of joint damage in rheumatoid arthritis. Adv from synovial biopsy and tissue analysis. Arthritis Rheum 43:2619-2633.
35. Targan SH, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, and Rutgeerts PJ (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Engl J Med 337:1029-1035.
36. Van de Putte LBA, Rau R, Breedveld FC, Schattenkirchner M, Emery P, Burmester GR, Zeidler H, Dressler R, Compagnone D, and Kempeni J(2000) One year efficacy results of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis. Arthritis Rheum 43 (Suppl 9):1218.
37. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, and Burge DJ (1999) A trial of etanercept, a recombinant TNF-alpha receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253-259.
38. Winer J, Jung CKS, Shackel I, and Williams PM (1999) Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 270:41-49.
39. Wu H, Lima WF, and Crooke ST (1999) Properties of cloned and expressed human RNase H1. J Biol Chem 274:28270-28278.
40. Yu R, Zhang H, Geary RS, Graham M, Masarjian L, Lemonidis K, Crooke R, Dean NM, and Levin AA (2001) Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice. J Pharmacol Exp Ther 296:388-395.
41. Zhang H, Cook J, Nickel J, Yu R, Stecker K, Myers K, and Dean NM (2000) Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat Biotechnol 18:862-867.